Trium Analysis Online GmbH
Industry / private company
Location:
München,
Germany (DE)
ISNI: -
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (2017)
Harbeck N, Saupe S, Jaeger E, Schmidt M, Kreienberg R, Mueller L, Otremba BJ, et al.
Journal article
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (vol 25, pg 1551, 2014) (2017)
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, et al.
Journal article
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression (2014)
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, et al.
Journal article